|
|
|
| Effect of endocrine therapy on hormone receptor positive breast cancer and its relationship with ESR1 gene locus |
| GU Bing1 WU Danping2 ZHANG Jingjing1 |
1.Department of General Surgery, the Fifth People′s Hospital of Changshu City, Jiangsu Province, Suzhou 215500, China;
2.Department of Thyroid and Breast Surgery, the First People′s Hospital of Changshu City, Jiangsu Province, Suzhou 215500, China |
|
|
|
Abstract Objective To study the effect of endocrine therapy on hormone receptor positive breast cancer and its relationship with ESR1 gene locus (rs2077647 and rs3798759). Methods Eighty-six patients with hormone receptor positive breast cancer admitted to the Fifth People′s Hospital of Changshu City in Jiangsu Province from January 2014 to December 2018 were selected as study objects. All patients were treated with endocrine therapy and ESR1 single nucleotide polymorphisms (rs2077647 and rs3798759) were detected. The short-term efficacy of endocrine therapy was analyzed and its relationship with ESR1 single nucleotide polymorphisms was observed. Results Forty five patients of 86 patients with complete remission, partial remission and stable disease after endocrine therapy were included in ETR group, 41 patients with disease progression were classified into ETNR group. The proportion of genotype CC at rs2077647 in ETR group was significantly higher than that in ETNR group (P < 0.05), the proportion of TT genotype of rs3798759 was significantly lower than that of ETNR group (P < 0.05), and the proportion of TG genotype was significantly higher than that of ETNR group (P < 0.05). The proportion of allele C at rs2077647 in ETR group was significantly higher than that in ETNR group (P < 0.05), and the proportion of allele G at rs3798759 was significantly higher than that in ETNR group (P < 0.05). ESR1 gene polymorphism was an independent factor affecting the effect of endocrine therapy (P < 0.05). Conclusion The effect of endocrine therapy on hormone receptor-positive breast cancer is closely related to ESR1 single nucleotide polymorphisms (rs2077647 and rs3798759).
|
|
|
|
|
|
[1] 唐金海.乳腺癌70年[J].中国肿瘤外科杂志，2019，11（3）：153-154.
[2] 杨海波，高晋南，宋宛芝.单纯乳腺癌与乳腺癌合并甲状腺癌患者临床病理特征分析[J].中华肿瘤杂志，2019，41（8）：624-627.
[3] 马辰，王振宇，华建芬，等.老年女性乳腺癌新辅助内分泌治疗的临床进展[J].国际老年医学杂志，2019，40（2）：120-123.
[4] 李田宏，郭放，谢晓冬.2018年ASCO年会CDK4/6抑制剂联合内分泌治疗晚期乳腺癌最新进展解读[J].中华内分泌外科杂志，2019，13（2）：159-161.
[5] 武星星，王伏生，胡耀峰，等.乳腺癌内分泌治疗耐药相关信号通路的研究进展[J].癌症进展，2019，17（12）：1380-1384.
[6] 赵爽，陈双双，于正洪.ESR1基因改变在乳腺癌内分泌治疗耐药中的研究进展[J].临床肿瘤学杂志，2016，21（10）：947-951.
[7] 朱琳，杨顺娥.乳腺癌雌激素受体相关基因研究进展[J].现代肿瘤医学，2015，23（8）：1135-1138.
[8] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范（2007版）[J].中国癌症杂志，2009，19（6）：410-428.
[9] 中华人民共和国卫生部.中国常见恶性肿瘤诊治规范[M].北京：北京医科大学、中国协和医科大学联合出版社，1991：25-29.
[10] 朱蔼瑜，许宇媚，许晶，等.雄激素受体对雌激素受体阳性乳腺癌细胞增殖的抑制作用[J].医学研究生学报，2016，29（4）：354-358.
[11] 杨帏，李苏，邓颖斐，等.中国人群CYP2D6基因多态性及其与激素受体阳性早期乳腺癌他莫昔芬代谢的关系[J].实用医学杂志，2018，34（12）：1995-1999.
[12] 李英彬，郭茜，包文华，等.他莫昔芬对乳腺癌SK-BR-3细胞侵袭能力的影响及其机制[J].中华内分泌外科杂志，2019，13（5）：368-371.
[13] 陈岚，陈巍，李硕果.贞芪扶正胶囊联合他莫昔芬治疗雌激素受体阳性乳腺癌的临床研究[J].现代药物与临床，2018，33（5）：1172-1175.
[14] 丁佩剑，金秀菊，孙宝信.人类单核苷酸多态性研究进展[J].临床和实验医学杂志，2016，15（12）：1235-1238.
[15] 高启龙，张新峰，耿良，等.UGT2B4基因RS1826690单核苷酸多态性对乳腺癌新辅助化疗病理完全缓解的影响[J].中华医学杂志，2018，98（16）：1242-1245.
[16] 叶长生，姚广裕.检测循环肿瘤DNA中ESR1突变在晚期乳腺癌治疗中的价值[J].循证医学，2016，16（3）：143-144.
[17] 李娟，李萍萍，刘洁，等.抑癌基因LKB1与乳腺癌他莫昔芬耐药性之间的关系[J].现代肿瘤医学，2018，26（20）：3184-3189.
[18] 王炜，项晶晶，周虹，等.乳腺黏液癌HER2基因表达特征分析[J].中华病理学杂志，2015，44（4）：278-279.
[19] Ghali RM，Al-Mutawa MA，Al-Ansari AK，et al. Differential association of ESR1 and ESR2 gene variants with the risk of breast cancer and associated features：a case-control study [J]. Gene，2018，651（1）：194-199.
[20] 殷玉莲，张卫红，周悦，等.ERα基因单核苷酸多态性与乳腺癌应用芳香化酶抑制剂引发骨丢失的相关性研究[J].实用肿瘤学杂志，2018，32（1）：14-18. |
|
|
|
